

## **Germline variation in inflammation-related pathways and risk of Barrett's esophagus and esophageal adenocarcinoma**

Matthew F. Buas<sup>1</sup>, Qianchuan He<sup>1</sup>, Lisa G. Johnson<sup>1</sup>, Lynn Onstad<sup>1</sup>, David M. Levine<sup>2</sup>, Aaron P. Thrift<sup>3</sup>, Puya Gharahkhani<sup>4</sup>, Claire Palles<sup>5</sup>, Jesper Lagergren<sup>6,7</sup>, Rebecca C. Fitzgerald<sup>8</sup>, Weimin Ye<sup>9</sup>, Carlos Caldas<sup>10</sup>, Nigel C. Bird<sup>11</sup>, Nicholas J. Shaheen<sup>12</sup>, Leslie Bernstein<sup>13</sup>, Marilie D. Gammon<sup>14</sup>, Anna H. Wu<sup>15</sup>, Laura J. Hardie<sup>16</sup>, Paul D. Pharoah<sup>17</sup>, Geoffrey Liu<sup>18</sup>, Prasad Iyer<sup>19</sup>, Douglas A. Corley<sup>20,21</sup>, Harvey A. Risch<sup>22</sup>, Wong-Ho Chow<sup>23</sup>, Hans Prenan, Laura Chegwidden, Sharon Love, Stephen Attwood, Paul Moayyedi, David MacDonald, Rebecca Harrison, Peter Watson, Hugh Barr, John deCaestecker, Janusz Jankowski<sup>\*24</sup>, Ian Tomlinson<sup>\*5</sup>, David C. Whiteman<sup>25</sup>, Stuart MacGregor<sup>4</sup>, Thomas L. Vaughan<sup>1,26</sup>, Margaret M. Madeleine<sup>1,26\*</sup>

### **\*- equal contribution**

<sup>1</sup>Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.

<sup>2</sup>Department of Biostatistics, University of Washington, School of Public Health, Seattle, Washington, USA.

<sup>3</sup>Department of Medicine, Baylor College of Medicine, Houston, TX, USA

<sup>4</sup>Queensland Institute of Medical Research Berghofer Medical Research Institute Brisbane, Queensland, Australia.

<sup>5</sup>Wellcome Trust Centre for Human Genetics and NIHR Comprehensive Biomedical Research Centre, University of Oxford, Oxford, UK.

<sup>6</sup>Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.

<sup>7</sup>Division of Cancer Studies, King's College London, United Kingdom.

<sup>8</sup>Medical Research Council (MRC) MRC Cancer Unit, Hutchison-MRC Research Centre, University of Cambridge, Cambridge, UK.

<sup>9</sup>Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.

<sup>10</sup>Cancer Research UK, Cambridge Institute, Cambridge, UK.

<sup>11</sup>Department of Oncology, Medical School, University of Sheffield, Sheffield, UK.

<sup>12</sup>Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, University of North Carolina, Chapel Hill, North Carolina, USA.

<sup>13</sup>Department of Populations Sciences, Beckman Research Institute and City of Hope Comprehensive Cancer Center, Duarte, California, USA.

<sup>14</sup>Department of Epidemiology, University of North Carolina, Chapel Hill, North Carolina, USA.

<sup>15</sup>Department of Preventive Medicine, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, California, USA.

<sup>16</sup>Division of Epidemiology, University of Leeds, Leeds, UK.

<sup>17</sup>Department of Oncology, University of Cambridge, Cambridge, UK ; Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.

<sup>18</sup>Pharmacogenomic Epidemiology, Ontario Cancer Institute, Toronto, Ontario, Canada M5G 2M9.

<sup>19</sup>Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.

<sup>20</sup>Division of Research, Kaiser Permanente Northern California, Oakland, California, USA.

<sup>21</sup>San Francisco Medical Center, Kaiser Permanente Northern California, San Francisco, California, USA.

<sup>22</sup>Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, CT, USA

<sup>23</sup>Department of Epidemiology, MD Anderson Cancer Center, Houston, TX, USA

<sup>24</sup>University Hospitals Coventry and Warwickshire and University of Warwick, Coventry, UK.

<sup>25</sup>Cancer Control, QIMR Berghofer Medical Research Institute, Brisbane, Australia.

<sup>26</sup>Department of Epidemiology, University of Washington, School of Public Health, Seattle, Washington, USA.

**\*Correspondence: [mmadelei@fredhutch.org](mailto:mmadelei@fredhutch.org)**

## Abstract

Esophageal adenocarcinoma (EA) incidence has risen sharply in Western countries over recent decades. Local and systemic inflammation, operating downstream of disease-associated exposures, is considered an important contributor to EA pathogenesis. Several risk factors have been identified for EA and its precursor, Barrett's esophagus (BE), including symptomatic reflux, obesity, and smoking. The role of inherited genetic susceptibility remains actively investigated. To explore whether germline variation related to inflammatory processes influences susceptibility to BE/EA, we used data from a genome-wide association study (GWAS) of 2,515 EA cases, 3,295 BE cases, and 3,207 controls. Our analysis included 7,863 single nucleotide polymorphisms (SNPs) in 449 genes assigned to five pathways: cyclooxygenase (COX), cytokine signaling, oxidative stress, human leukocyte antigen, and NF $\kappa$ B. A novel analytic framework, termed telescoping principal components analysis (ts-PCA), was employed to evaluate pathway-level and gene-level associations with disease risk. We identified a significant signal for variation in the COX pathway in relation to BE risk ( $P=0.0059$ , FDR  $q=0.03$ ), and in gene-level analyses found an association with *MGST1* (microsomal glutathione-S-transferase 1;  $P=0.0005$ ,  $q=0.005$ ). Assessment of 36 *MGST1* SNPs identified 14 variants associated with elevated BE risk ( $q<0.05$ ). Of these, four variants were subsequently confirmed ( $P<10^{-4}$ ) in a meta-analysis encompassing an independent set of 1,851 BE cases and 3,496 controls. Three of these SNPs (rs3852575, rs73112090, rs4149204) were associated with similar elevations in EA risk. This study provides the most comprehensive evaluation to date of inflammation-related germline variation in relation to risk of BE/EA, and suggests that variants in *MGST1* influence disease susceptibility.

## Introduction

The incidence of esophageal adenocarcinoma (EA) has risen rapidly over recent decades in Western countries [1, 2, 3, 4, 5]. EA typically arises within a metaplastic precursor epithelium known as Barrett's esophagus (BE) [6, 7]. Established risk factors for EA and BE include symptomatic gastroesophageal reflux disease (GERD), abdominal adiposity, tobacco smoking, European ancestry, and male sex [7, 8, 9, 10]. A prevailing conceptual model has linked chronic inflammation and genomic instability to EA pathogenesis [7]. Several exposures associated with elevated disease risk, such as reflux, obesity, and smoking, increase levels of local and systemic inflammation, while use of non-steroidal anti-inflammatory drugs (NSAIDs) and statins (which may have anti-inflammatory properties), has been associated with reduced risk [11, 12, 13]. It remains poorly understood, however, whether and to what extent inherited genetic variation in specific genes and pathways implicated in inflammatory signaling may modulate disease susceptibility and interact with these established risk factors.

A biologic link between chronic inflammation and cancer risk has long been appreciated [14, 15, 16]. Inflammation may act at multiple stages of disease development to disrupt tissue homeostasis, induce aberrant proliferative responses, modulate the tumor microenvironment, and compromise immune surveillance [17, 18, 19, 20, 21]. Inflammatory physiological changes such as oxidative stress are known to exert downstream genotoxic effects [22], and when sustained over extended periods, can promote the emergence of cancer-initiating mutations. In the esophagus, long-term exposure to gastric acid or bile salts results in the release of pro-inflammatory cytokines (eg, interleukin-8), activation of nuclear factor kappa-light-chain-enhancer of activated B cells (NF- $\kappa$ B) and cyclooxygenase-2 (COX2), alterations in gene expression, and direct tissue damage to the squamous epithelium [23, 24, 25, 26, 27]. Cigarette smoking can also expose the esophagus to deleterious toxins while simultaneously inducing systemic inflammatory responses based on activation of cytokine signaling, NF $\kappa$ B activation, and COX pathway stimulation [28, 29, 30]. Abdominal adiposity and obesity have been associated with elevated circulating levels of pro-inflammatory mediators such as tumor necrosis factor- $\alpha$  (TNF $\alpha$ ), C-reactive protein (CRP), interleukin-6 (IL-6), and leptin [31, 32, 33]. These elevated inflammation markers are likely consequences of adipose tissue inflammation. Inflammation may therefore sustain pathogenesis at several points and through multiple pathways, from development of early lesions through cancer progression.

Recent large-scale GWAS have provided the most comprehensive assessments to date of inherited genetic susceptibility to BE and EA [34, 35, 36, 37, 38]. Novel associations have been identified with variants in or near several transcription factors implicated in embryonic esophageal development, a transcriptional co-activator, and the human leukocyte antigen (HLA) region. It remains likely, however, that additional loci that did not satisfy the commonly-used, stringent statistical threshold ( $p < 5 \times 10^{-8}$ ) may be involved in modifying disease risk. In this regard, pathway-based analytic methods can offer significant advantages over conventional genome-wide analyses. Pathway approaches simultaneously reduce the number of statistical comparisons and increase power by aggregating large numbers of low-magnitude signals [39]; importantly, such methods allow for the systematic analysis of coherent biological processes most likely to be implicated in disease etiology.

Given the central role of inflammation in BE and EA pathogenesis, we examined genetic variation in five inflammation-related pathways—COX, cytokine signaling, oxidative stress, HLA, and NF $\kappa$ B—based on a novel principal components-based pathway analysis framework. Using genotyping data from the International Barrett's Esophagus and Adenocarcinoma Consortium (BEACON) GWAS of 2,515 EA cases, 3,295 BE cases, and 3,207 controls, we selected a total of 7,863 SNPs in 449 genes and assessed associations with risks of BE and EA in a pre-specified tiered fashion, first at the pathway level, next at the gene level, and ultimately at the SNP level.

## **Methods**

### **Study population and SNP genotyping**

The BEACON GWAS included men and women diagnosed with EA or BE, and control participants pooled from 14 individual studies conducted in Western Europe, Australia, and North America over the past 20 years. Detailed study population characteristics and genotyping protocols have been published [34]. The current analysis employed a pooled dataset [40] that included participants of European ancestry from the BEACON GWAS, additional BE and EA patients from the UK Barrett's Esophagus Gene Study and the UK Stomach and Oesophageal Cancer Study (SOCS), respectively [34], and additional control participants from a hospital-based case-control study of melanoma conducted at the MD Anderson Cancer Center (Houston, TX) [41]. Genotyping of buffy coat or whole blood DNA from

all participants was conducted using the Illumina Omni1M Quad platform, in accordance with standard quality control procedures [42]. All participants gave written informed consent, and this project was approved by the ethics review board of the Fred Hutchinson Cancer Research Center. We selected all unrelated participants with <2% missing genotyping calls; thus the final study sample included 2,515 EA cases, 3,295 BE cases, and 3,207 controls. Three control participants were excluded from analyses involving BE cases, because of familial relation to cases.

### **Selection of genes in inflammation-related pathways**

Five pathways implicated in chronic inflammation were selected for analysis: 1) cyclooxygenase (COX) (n=40 genes), 2) pro- and anti-inflammatory cytokines (n=198 genes), 3) oxidative stress (n=117 genes), 4) HLA (32 genes), and 5) NF- $\kappa$ B (n=125 genes). Selected genes in each of these pathways (**Table S1**) were identified based on an extensive survey of the prior literature on inflammation in cancer biology [17, 21, 43, 44] and as described in public databases (eg. KEGG, Biocarta). Our choices were further informed by recent papers focused on inflammation in laboratory-based studies of esophageal pathogenesis [45, 46, 47, 48, 49], clinical series [50, 51, 52], and epidemiologic studies [53, 54, 55, 56].

### **SNP selection**

SNPs selected for this study are located in or near ( $\pm$  2.0 kilobases) the genes chosen for analysis. We excluded from consideration SNPs that failed Illumina quality measures or standard quality control procedures [42]. Specifically, SNPs were excluded if any of the following criteria were satisfied: i) Illumina GenTrain score < 0.6 or cluster separation < 0.4; ii) >5% missing call rate over included samples; iii) discordant genotype calls in any pair of duplicate study samples; iv) Mendelian error in either one of the HapMap QC trios or the small number of families identified in the BEACON data; v) significant departure from Hardy-Weinberg Equilibrium ( $P < 10^{-4}$ ); and vi) minor allele frequency (MAF) < 1%. Imputation of missing values for genotyped SNPs was conducted using SHAPEIT [57]. After imposing the above filters, we identified all available Omni1M SNPs located within the selected genes of each inflammation-related pathway. Segments of 2.0 kilobases of flanking sequence proximal to the gene start sites and distal to the 3'UTRs were also included, based on gene boundaries defined in hg19/GRChB37.

No Omni1M SNPs were available for 16 genes initially selected (cytokines: n=14, oxidative stress: n=2) (Table S1). Minor and major alleles were reported throughout using the 'plus' strand designation.

## Statistical analysis

We examined each of the five inflammation-related pathways using a new approach involving principal components analysis (PCA). We first constructed a genotype matrix comprising all SNPs assigned to the indicated pathway, inclusive of case patients of the selected type (BE or EA) and all control participants. Individual SNP variables, coded as 0, 1, or 2 minor alleles, were first standardized across participants to have a mean of zero and standard deviation (SD) of 1. The first N principal components (PCs) that captured  $\geq 50\%$  of the genotypic variance of the pathway were selected. Association between a given pathway and risk of BE or EA was assessed using the likelihood ratio test (LRT). Two logistic regression models were compared: i) a full model containing N pathway-level PCs ( $PC_{1,p} \dots PC_{N,p}$ ), age, sex, and the first four PCs derived from ancestry-informative markers (AIM) to account for population stratification ( $PC_{1,AIM} - PC_{4,AIM}$ ) [40]; and ii) a reduced model containing only age, sex and  $PC_{1,AIM} - PC_{4,AIM}$ . HLA loci were excluded from the set of ancestry-informative markers, as described previously [34]. We selected pathways for which the resulting LRT P value was  $< 0.05$ , after correction for multiple comparisons (n=5) via the false discovery rate method (FDR) [58].

To prioritize genes within a selected pathway for further analysis at the gene level, we examined SNP loading factors within the first pathway-level principal component ( $PC_{1,p}$ ). SNPs within  $PC_{1,p}$  were rank-ordered by the absolute values of their loading coefficients. The first ten genes represented by these rank-ordered SNPs were advanced to gene-level analysis. PCA was conducted for each of these genes using a genotype matrix comprised of all SNPs assigned to the indicated gene; the top three PCs were selected, or the top N PCs, if  $> 3$  were required to capture  $\geq 50\%$  of the genotypic variance. Association between a given gene and risk of BE or EA was assessed as above using the LRT, comparing i) a full model inclusive of the selected gene-level PCs ( $PC_{1,g} - PC_{N,g}$ ), age, sex, and  $PC_{1,AIM} - PC_{4,AIM}$ ; and ii) a nested reduced model containing age, sex, and  $PC_{1,AIM} - PC_{4,AIM}$ . Multiple comparisons (n=10) were accounted for via the FDR method.

Genes satisfying FDR  $q < 0.05$  were selected for additional analysis at the SNP level. Unconditional logistic regression was used to compute odds ratios (ORs) for risk of EA or BE associated with a given SNP variant, under an additive model (per-allele) with adjustment for age, sex, and PC<sub>1,AIM</sub>-PC<sub>4,AIM</sub>, and correcting for multiple comparisons via the FDR method. Observed associations were visualized graphically using LocusZoom [59].

We also investigated whether the association between allelic variation in selected SNPs and risk of BE or EA varied by exposure to key risk factors which can promote inflammation (symptomatic reflux, high body mass index (BMI, kg/m<sup>2</sup>), and cigarette smoking) or inhibit inflammation (use of NSAIDs). These analyses used a subset of the overall study population for which such exposure data were presently available; BE/EA case patients from the UK, and control participants from MD Anderson, described previously, were excluded. Reflux symptoms, BMI, smoking history, and NSAID use were defined categorically in stratified analyses (reflux:  $\geq$ weekly symptoms yes or no; BMI: <25, 25-29, 30-34, or 35+; smoking: ever or never, or pack-years: 0, >0 & <15, 15-29, 30-44, or 45+; NSAID use: ever or never). Pack-year smoking history and BMI were modeled as continuous covariates in tests for interaction. Nested logistic regression models were compared by the likelihood ratio test to full models additionally containing an interaction term. We also derived a composite “inflammation score” using factor analysis [60], based on BMI (<25, 25-<30, or 30+), weekly GERD symptoms (yes or no), and ever smoking (yes or no). A single factor was retained and the individual factor score for each participant was estimated based on BMI, history of GERD symptoms and smoking status, and the factor loadings for each variable. In stratified analyses, the continuous “inflammation score” was categorized into three levels (low, medium, or high) based on tertile cutoffs among control participants. Possible interactions with the continuous score and selected SNPs were examined as above. Statistical analyses were conducted using STATA/SE version 14 (College Station, TX).

An independent dataset comprised of 1,851 BE patients and 3,496 control participants from the U.K., described previously [35], was used for validation studies. Genotyping was performed on the Illumina Human 660W-Quad and Human 1.2M-Duo array platforms. Summary statistics for the associations of 13 genotyped SNPs at the *MGST1* locus and risk of BE were extracted and used in a

subsequent meta-analysis based on the inverse-variance weighting method [61]. Validation analyses were conducted in R v3.2.1

## Results

### Characteristics of study participants

The distributions of demographic and behavioral characteristics among control participants, BE case patients, and EA case patients are shown in **Table 1**. EA cases were somewhat older and more often male relative to controls and BE cases. The percentage reporting ever having smoked cigarettes was higher among BE and EA cases than among controls, and heavy smoking (45+ pack years) was more prevalent among EA cases. Obesity (BMI 30+) and weekly reported reflux or heartburn were more prevalent among BE and EA cases than among controls. NSAID use appeared similar across the three groups. Relative to controls, a substantially higher percentage of participants with BE and EA were classified as having a high composite “inflammation score”, based on BMI, smoking history, and reflux symptoms.

### Pathway-level associations with risk of BE or EA

To obtain a top-level, global assessment of the association between germline variation within five selected inflammation-related pathways (COX, cytokine signaling, oxidative stress, HLA, and NFκB) and risk of BE or EA, we employed a PCA-based approach (**Figure 1**). Based on logistic regression analyses that incorporated a subset of the derived principal components as predictor variables and assessed associations with disease risk, we identified a single significant ( $P < 0.05$ ) pathway-level signal for risk of BE: the COX pathway ( $P = 0.006$ ) (**Table 2**). This association remained significant after accounting for multiple comparisons (FDR  $q = 0.03$ ). None of the five pathways examined were found to be associated ( $P < 0.05$ ) with risk of EA.

### Gene-level associations with risk of BE

The observed association between variation in the COX pathway and risk of BE could reflect the summation of a large number of small, distributed signals across many genes, or represent relatively concentrated signals in a single or small number of genes. To evaluate these possibilities and determine whether or not individual COX pathway-related genes in particular might account for the identified association, we undertook gene-level analyses using the same PCA framework used at the pathway level (**Figure 1**). Of the 40 genes assigned to the COX pathway, we prioritized 10 for further analysis, based on their contribution to the overall pathway-level genotypic variance, as reflected in rank-ordered SNP loading coefficients in the first principal component. Among these 10 genes assessed for associations with risk of BE (**Table 3**), only a single gene exhibited a significant signal: microsomal glutathione S-transferase 1 (*MGST1*) ( $P=0.0005$ ). This association remained significant after correction for multiple comparisons (FDR  $q=0.005$ ). A borderline-significant ( $P=0.07$ ) association was also observed for gene-level variation in *MGST1* and risk of EA (**Table S2**).

#### **SNP-level associations with risk of BE**

Individual SNPs located within or in proximity to ( $\pm 2.0$  kb) the *MGST1* locus were assessed for associations with risk of BE. Among 36 such variants examined, 23 were found to exhibit a nominally significant ( $P<0.05$ ) signal. 14 of these 23 remained significant after correction for ( $n=36$ ) multiple comparisons (FDR  $q<0.05$ ) (**Table 4**). The minor alleles at all 14 SNPs were associated with elevated disease risk, with ORs ranging in magnitude from 1.10-1.38. The most significant association was for rs4149203 C>T (OR=1.16,  $P=9.0 \times 10^{-5}$ ,  $q=0.001$ ). A LocusZoom plot of the 36 assessed SNPs revealed a cluster of six nearby variants in high linkage disequilibrium (LD,  $r^2>0.8$ ) with rs4149203 (**Figure 2**). A second cluster of six SNPs satisfying FDR  $q<0.05$  was situated at the 5' end of the *MGST1* locus (**Figure S2**); modest to moderate LD was observed between rs2239676, the top-ranked SNP in this region, and the other five variants in close proximity. Based on data from the NIH Roadmap Epigenome Project [62], three of these 5' polymorphisms – rs2239676, rs2239677, and rs2975138 – lie within a 1.2-kilobase segment that spans the *MGST1* transcriptional start site and is characterized by active chromatin marks in esophageal tissue (**Figure S3**). Among the 14 significant susceptibility signals identified for BE, 11

were associated with risk of EA ( $P<0.05$ ). Eight of these 11 remained significant after adjustment for multiple comparisons ( $q<0.05$ ), with observed ORs ranging from 1.10 to 1.17 (**Table S3**).

### **Assessment of top *MGST1* SNPs and risk of BE in an independent study sample**

We next evaluated whether any of the 14 *MGST1* variants associated with risk of BE in our primary analysis were similarly associated with altered BE risk in a large, independent sample set from the U.K. comprised of 1,851 BE patients and 3,496 control participants. 13 of the 14 SNPs were available for analysis, and of these, four variants exhibited borderline-significant ( $P<0.10$ ) associations with BE: rs3852575, rs4149204, rs7312090, rs4149203 (**Table 5**). Odds ratios for these SNPs were similar to those obtained in the primary analysis, though slightly reduced in magnitude (1.08 versus 1.16). In a subsequent meta-analysis, the  $P$  values for all four of these variants were highly significant ( $P<10^{-4}$ ), with an additional six SNPs satisfying  $P<0.05$ .

### **Expression quantitative trait locus (eQTL) analysis**

To explore whether or not any of the 14 individual *MGST1* SNPs in Table 4 may also be correlated with altered *MGST1* RNA expression levels in the esophagus, we conducted *in silico* eQTL analyses using the Genotype-Tissue Expression (GTEx) database [63]. Of the 13 SNPs with available genotyping and expression data in esophageal mucosa, two variants were associated ( $P<0.05$ ) with differential *MGST1* expression: rs4149186 A>C ( $P=7.9 \times 10^{-5}$ ) and rs2975138 G>A ( $P=1.20 \times 10^{-7}$ ) (**Table S4**). A third variant, rs4149203 C>T, reached borderline significance ( $P=0.074$ ). For each of these SNPs, the allele found to be associated with *increased* risk of BE was also correlated with *reduced* expression of *MGST1* (**Figure S1**).

### **Assessment of gene-environment interactions**

We next conducted stratified analyses and evaluated interactions between several risk factors for BE/EA (smoking, obesity, reflux, and NSAID use) and the top *MGST1* variants ( $q<0.01$ ) associated with risk of BE. No statistically significant interactions were observed (**Table S5**).

## Discussion

Chronic inflammation may occur as a result of multiple exposures established as risk factors for BE and EA (gastroesophageal reflux, obesity, smoking) and is thought to represent a common pathway underlying the emergence and progression of these conditions [7] and new reference Tselepis. This study represents the first systematic examination of the relationship between germline genetic variation in inflammation-related pathways—COX, cytokine signaling, oxidative stress, HLA, and NF $\kappa$ B—and risks of BE and EA, using a novel principal components-based analytic framework (ts-PCA). Drawing on genetic data from a large consortium-based GWAS [34], we found a significant association between variation in the COX pathway and risk of BE, and identified a gene-level signal for *MGST1*. SNP-level analyses identified 14 individual *MGST1* variants associated with elevated disease risk, including several intronic variants that were subsequently confirmed ( $P < 10^{-4}$ ) in a meta-analysis encompassing a large independent sample set of additional BE cases and controls.

*MGST1* is one of three microsomal glutathione S-transferase (GST) enzymes in humans, and belongs to a larger GST gene family encoding a number of proteins responsible for neutralizing oxidative stress through conjugation of endogenous and xenobiotic lipophilic electrophiles with glutathione [64, 65, 66]. *MGST1* shares ~40% sequence homology at the amino acid level with prostaglandin E synthase (PTGES, formerly *MGST1L1*), a key enzyme that acts downstream of cyclooxygenases to catalyze the production of PGE<sub>2</sub> from PGH<sub>2</sub> [67]. *MGST1-3* and PTGES all belong to the “MAPEG” super-family of membrane-associated proteins in eicosanoid and glutathione metabolism. Microsomal GST1 is localized to the endoplasmic reticulum and outer mitochondrial membrane, and plays an important role in suppressing lipid peroxidation and protecting mitochondrial integrity [65]. Multiple alternatively spliced transcripts arise from the *MGST1* gene locus, and the *MGST1* promoter region has been shown to be transcriptionally responsive to oxidative stress [64]. Some evidence exists for an association between genetic variation in the *MGST1* gene and altered risk of colorectal cancer in Han Chinese [68].

The 14 *MGST1* SNPs found to be associated with risk of BE in our primary analysis were geographically clustered into two main groups, one at the 3' end of the gene, and the other at the 5' end, and may reflect two (or more) independent signals. The most significant association was for rs4149203 C>T, a 3' intronic variant in strong LD with the six other associated 3' SNPs ( $r^2 > 0.8$ ). Four of these seven

SNPs, including rs4149203, were confirmed in the meta-analysis phase of our validation studies. These variants lie in a region defined by enhancer histone marks, and modify predicted sequence motifs for several transcription factors (eg. POU5F1, SOX, BRCA1, FOXP1; **Table S6**) [69]. Of interest, *FOXP1* was identified as a susceptibility locus for EA in our previous report [34], and recently replicated in an independent study [38]. Published eQTL data from a study of gene expression in various brain regions indicated that rs4149203 (and correlated SNPs) may be associated with altered *MGST1* expression in cerebellum [69, 70]. Proximity of several of these variants to an *MGST1* splice junction also suggests a potential influence on (alternative) splicing regulation.

At the 5' end of *MGST1*, rs2239676 C>G was the top signal identified among a cluster of six variants associated with BE risk. Three of these variants lie in close proximity to the *MGST1* transcriptional start site, within a region characterized as active chromatin in esophageal tissue; recruitment of Pol II and several transcription factors (eg, Hey1, MYC/MAX) has been reported [62]. Our *in silico* eQTL analyses based on data from the GTEx project indicated that rs2975138 G>A and rs4149186 A>C, in particular, correlate with reduced *MGST1* expression in esophageal mucosa. The rs2975138 variant modifies predicted motifs for estrogen receptor-alpha, Pax5, and Zfx, while rs4149186 alters recognition sequences for FoxA, FoxJ2, and Nkx2, among other regulators [69]. Given that these variants failed to validate in the Oxford (U.K.) dataset, however, their association with BE risk remains questionable. As a further qualification, we note that GTEx eQTL analyses appear to have been conducted using normal esophageal squamous epithelium, which based on emerging findings, may not in fact be the tissue of origin for Barrett's epithelium [71, 72].

The findings described above suggest that several of the identified variants may play a role in influencing *MGST1* RNA expression levels. Additional studies, however, are warranted to investigate potential relationships between selected variants and altered tissue-specific *MGST1* expression, and to explore a possible causal basis for the observed genetic associations. Since BE and EA often arise within an epithelium chronically exposed to refluxate and to cigarette-associated toxins (ie. associated with inflammation), it would be of interest to determine experimentally whether *MGST1* plays a protective role in counteracting such insults and maintaining tissue homeostasis.

Given that BE is the only known precursor of EA, one expectation is that risk factors linked to altered risk of BE would be associated with similar alterations in risk of EA. In this study, variation in the COX pathway as a whole met the threshold for significance in relation to risk of BE, but not EA. Our subsequent analyses, however, revealed that a number of the individual *MGST1* SNPs found to be associated with risk of BE did in fact exhibit similar associations with risk of EA (**Table S3**). With respect to top SNP-level signals, the associated ORs for EA were in the same direction as, and of comparable magnitude to, those observed for BE. This strong level of concordance suggests that the identified variants, if causal, may influence disease risk primarily at the level of BE, rather than progression from BE to EA.

Genes in our analysis assigned to the COX pathway included those coding for the two COX enzymes, prostaglandin and thromboxane synthases and receptors, aldo-keto reductases, peroxisome proliferator-activated receptors (PPAR), matrix metalloproteinases, microsomal glutathione S-transferases, and a small assortment of growth factors (VEGF) and interleukins or interleukin receptors. Previous candidate gene-based studies have reported associations between germline variation in *PTGS2* (*COX-2*) and altered risk of EA [73, 74], while independent epidemiologic evidence has supported an inverse association between use of NSAIDs (inhibitors of COX-1 and COX-2 activity) and risk of EA [11, 12]. Our gene-level and SNP-level analyses did not include all genes assigned to the COX pathway (e.g. *PTGS2*), as only a limited subset were advanced for further study based on pre-specified selection criteria (the top 10 genes in PC1, see **Table 3**). It remains a possibility, therefore, that associations of disease risk with variation in other COX pathway genes may be evident in our dataset, and contribute in part to the observed pathway-level signal.

One of the main strengths of our study was the use of a PCA framework to assess pathway-level and gene-level associations between germline genetic variation and risk of BE or EA. PCA is an effective strategy to reduce data dimensionality. In this report, we adapted PCA to genetic pathway or gene analysis, and designed a hierarchical strategy, which we call “telescoping (ts)-PCA”, to identify genetic variants associated with traits. Application of ts-PCA to GWAS data offered key advantages over conventional marginal analyses that are based exclusively on evaluation of individual SNPs. First, by aggregating signals across multiple genes (of a given pathway) or across multiple SNPs (of a given

gene), the PCA method increased our ability to detect associations characterized by multiple, independent, distributed low-magnitude signals. Second, by reducing the dimensionality of the genotype matrix, PCA appreciably reduced the number of multiple comparisons and effectively increased our statistical power. Our tiered analysis plan further specified that only (a subset of) genes within significant pathways were assessed at the gene level, and only variants within significant genes were evaluated at the SNP level.

Another important strength was the use of pooled data from the BEACON GWAS, which provided the largest sample size to date in the evaluation of inflammation-related germline variation and risks of EA and BE. As a consequence of analyzing both BE and EA, we had the opportunity to compare genetic variation associated with risk of a neoplastic precursor lesion and the cancer that arises from it. The availability of linked epidemiologic data for smoking history, BMI, reflux, and NSAID use further allowed for exploratory evaluation of gene-environment interactions. Our assessment of 7,863 SNPs in 449 genes assigned to five pathways significantly expands past candidate gene-based efforts to examine genetic variation in inflammation-related loci in relation to risk of EA and BE.

This study also had certain limitations. First, while our tiered analysis scheme enabled us to restrict the number of comparisons and boost statistical power, it also narrowed the scope of our analysis and potentially resulted in missed association signals. Variation in four of the five included pathways was not examined at the gene or SNP level, while only 25% of the genes in the COX pathway were advanced beyond pathway-level assessment. Second, given the hierarchical nature of our statistical analysis, whereby we first assessed significance at the pathway level, and then proceeded to the gene level only for 'significant' pathways, the initial P values obtained for individual genes, and subsequently for individual SNPs, should be interpreted as the P values conditional on that pathway (or gene) already being selected, i.e.,  $P(A|B)$ , where B represents the event that a pathway (or gene) is selected, and A represents the event that a gene (or SNP) is significant. This conditional probability framework was well suited to our use of ts-PCA as a discovery-phase approach for identifying potential novel association signals, which were then subsequently confirmed in an independent sample set. Third, missing data for smoking, obesity, reflux, and NSAID use in a sizable fraction of participants reduced our statistical power to evaluate gene-environment interactions (**Table S7**). Most of the missing data for these covariates

resulted from study questionnaires not including questions related to these exposures. Further analyses in expanded sample sets are essential, particularly in light of a recent study of colorectal cancer risk describing a genome-wide significant interaction between a variant located ~900 kb downstream from the *MGST1* locus and aspirin or NSAID use [75]. Fourth, while our study provided broad coverage of several major biological pathways of probable relevance to BE/EA, it is almost certain that a number of important genes or genomic loci were not included. Cytokine signaling, NF $\kappa$ B activity, and oxidative stress, for example, represent complex processes likely influenced by many hundreds or more gene products and a large number of intergenic loci harboring both enhancer/insulator transcriptional elements and non-coding RNAs. The present analysis, however, was largely restricted to examining common germline variants located within or in close (2.0-kb) proximity to defined protein-coding genes.

In conclusion, our study represents the most comprehensive evaluation to date of inflammation-related inherited genetic variation in relation to risk of BE and EA. Using a PCA framework for pathway-level and gene-level analyses, we describe evidence for novel associations between variation at the *MGST1* locus and increased disease risk. It appears possible that certain associated variants may act to influence expression levels of *MGST1*, a gene with known roles in the cellular response to oxidative stress. Pending further validation in additional study populations, future studies are warranted to fine-map the identified association signals, assess experimentally the functional effects of these variants, and explore the biological role of *MGST1* in BE/EA pathogenesis.

## Acknowledgments

We thank Terri Watson, Tricia Christopherson, and Paul Hansen for their contributions in project management and organization of biospecimens/data. We thank Dr. Liam Murray (Queen's University Belfast, UK) for access to GWAS data derived from subjects enrolled in his past studies of EA and BE (FINBAR Study). Genotyping data for MD Anderson control participants [42] was obtained from dbGaP through accession number phs000187.v1.p1. Genotyping data generated in the BEACON GWAS has been deposited into dbGaP under accession number phs000869.v1.p1.

## Author contributions

Conception and design: M.M.M., Q.H., M.F.B., L.G.J., T.L.V. Participant recruitment: J.L., R.C.F., W.Y., C.C., N.C.B., N.J.S., L.B., M.D.G., A.H.W., L.J.H., P.D.P., G.L., P.I., D.A.C., H.A.R., W-H.C., D.C.W., T.L.V. Analysis and interpretation of data: M.F.B., Q.H., M.M.M., L.G.J., L.O., D.M.L., A.P.T., T.L.V. Drafting of the manuscript: M.F.B., M.M.M., Q.H., T.L.V. Study supervision: M.M.M. All authors critically revised the manuscript for intellectual content.

This work was also supported by the Esophageal Adenocarcinoma GenE

Consortia incorporating the ChOPIN project (grant C548/A5675) and Inherited Predisposition of neoplasia analysis of genomic DNA (IPOD) from AspECT (grant C548/A5675) and Clinical trials (grant C548/A5675); Cancer Research UK (AspECT, grants C548/A4584 and D9612L00090, and Histological Assessment Determining Epithelial Response (HANDEL), grant C548/A9085); AstraZeneca UK educational grant; University Hospitals of Leicester R and D grant; and AspECT (T91 5211 University of Oxford grant HDRMJQ0).

- [1] Yang PC, Davis S. Incidence of cancer of the esophagus in the US by histologic type. *Cancer*. 1988 Feb;61(3):612–617.
- [2] Blot WJ, Devesa SS, Kneller RW, Fraumeni JF. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. *JAMA : the journal of the American Medical Association*. 1991;265(10):1287–1289.
- [3] Steevens J, Botterweck AM, Dirx MJ, van den Brandt PA, Schouten LJ. Trends in incidence of oesophageal and stomach cancer subtypes in Europe. *European journal of gastroenterology & hepatology*. 2010 Jun;22(6):669–678. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/19474750>.
- [4] Thrift AP, Whiteman DC. The incidence of esophageal adenocarcinoma continues to rise: Analysis of period and birth cohort effects on recent trends. *Annals of Oncology*. 2012 Dec;23(12):3155–3162.
- [5] Vaughan TL, Fitzgerald RC. Precision prevention of oesophageal adenocarcinoma. *Nat Rev Gastroenterol Hepatol*. 2015 Apr;12(4):243–248. Available from: <http://dx.doi.org/10.1038/nrgastro.2015.24>.
- [6] Naef AP, Savary M, Ozzello L. Columnar-lined lower esophagus: an acquired lesion with malignant predisposition. Report on 140 cases of Barrett's esophagus with 12 adenocarcinomas. *J Thorac Cardiovasc Surg*. 1975 Nov;70(5):826–835.
- [7] Reid BJ, Li X, Galipeau PC, Vaughan TL. Barrett's oesophagus and oesophageal adenocarcinoma: time for a new synthesis. *Nature reviews Cancer*. 2010 Feb;10(2):87–101. Available from: <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2879265&tool=pmcentrez&rendertype=abstract>.
- [8] Lagergren J, Bergström R, Lindgren A, Nyrén O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. *N Engl J Med*. 1999 Mar;340(11):825–831. Available from: <http://dx.doi.org/10.1056/NEJM199903183401101>.
- [9] Vaughan TL, Davis S, Kristal A, Thomas DB. Obesity, alcohol, and tobacco as risk factors for cancers of the esophagus and gastric cardia: Adenocarcinoma versus squamous cell carcinoma. *Cancer Epidemiology Biomarkers and Prevention*. 1995 Mar;4(2):85–92. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/7742727>.

- [10] Chow WH, Blot WJ, Vaughan TL, Risch HA, Gammon MD, Stanford JL, et al. Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia. *Journal of the National Cancer Institute*. 1998 Jan;90(2):150–155. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/9450576>.
- [11] Vaughan TL, Dong LM, Blount PL, Ayub K, Odze RD, Sanchez CA, et al. Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett's oesophagus: A prospective study. *Lancet Oncology*. 2005 Dec;6(12):945–952. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/16321762>.
- [12] Liao LM, Vaughan TL, Corley DA, Cook MB, Casson AG, Kamangar F, et al. Nonsteroidal anti-inflammatory drug use reduces risk of adenocarcinomas of the esophagus and esophagogastric junction in a pooled analysis. *Gastroenterology*. 2012 Mar;142(3):442–452. Available from: <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3488768&tool=pmcentrez&rendertype=abstract>.
- [13] Kantor ED, Onstad L, Blount PL, Reid BJ, Vaughan TL. Use of statin medications and risk of esophageal adenocarcinoma in persons with Barrett's esophagus. *Cancer Epidemiology Biomarkers and Prevention*. 2012 Mar;21(3):456–461. Available from: <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3297725&tool=pmcentrez&rendertype=abstract>.
- [14] Rosin MP, Anwar WA, Ward AJ. Inflammation, chromosomal instability, and cancer: the schistosomiasis model. *Cancer Res*. 1994 Apr;54(7 Suppl):1929s–1933s.
- [15] Coussens LM, Werb Z. Inflammation and cancer. *Nature*. 2002;420(6917):860–867. Available from: <http://dx.doi.org/10.1038/nature01322>.
- [16] Hussain SP, Hofseth LJ, Harris CC. Radical causes of cancer. *Nat Rev Cancer*. 2003 Apr;3(4):276–285. Available from: <http://dx.doi.org/10.1038/nrc1046>.
- [17] Coussens LM, Werb Z. Inflammatory cells and cancer: think different! *J Exp Med*. 2001 Mar;193(6):F23–F26.
- [18] Thun MJ, Henley SJ, Gansler T. Inflammation and cancer: an epidemiological perspective. *Novartis Found Symp*. 2004;256:6–21; discussion 22–8, 49–52, 266–9.
- [19] Elinav E, Nowarski R, Thaiss CA, Hu B, Jin C, Flavell RA. Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. *Nature reviews Cancer*. 2013 Nov;13(11):759–71. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/24154716>.

- [20] Jinushi M. Yin and yang of tumor inflammation: How innate immune suppressors shape the tumor microenvironments. *International Journal of Cancer*. 2014 Sep;135(6):1277–1285. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/24272248>.
- [21] Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. *Cell*. 2011;144(5):646–674. Available from: <http://dx.doi.org/10.1016/j.cell.2011.02.013>.
- [22] Atsumi T, Singh R, Sabharwal L, Bando H, Meng J, Arima Y, et al. Inflammation amplifier, a new paradigm in cancer biology. *Cancer Research*. 2014 Jan;74(1):8–14. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/24362915>.
- [23] Kandulski A, Malfertheiner P. Gastroesophageal reflux disease—from reflux episodes to mucosal inflammation. *Nat Rev Gastroenterol Hepatol*. 2012 Jan;9(1):15–22. Available from: <http://dx.doi.org/10.1038/nrgastro.2011.210>.
- [24] Zhang F, Altorki NK, Wu YC, Soslow RA, Subbaramaiah K, Dannenberg AJ. Duodenal reflux induces cyclooxygenase-2 in the esophageal mucosa of rats: evidence for involvement of bile acids. *Gastroenterology*. 2001 Dec;121(6):1391–1399.
- [25] McAdam E, Haboubi HN, Griffiths AP, Baxter JN, Spencer-Harty S, Davies C, et al. Reflux composition influences the level of NF- $\kappa$ B activation and upstream kinase preference in oesophageal adenocarcinoma cells. *International Journal of Cancer*. 2014;8:527–535.
- [26] Green NH, Nicholls Z, Heath PR, Cooper-Knock J, Corfe BM, MacNeil S, et al. Pulsatile exposure to simulated reflux leads to changes in gene expression in a 3D model of oesophageal mucosa. *Int J Exp Pathol*. 2014 Jun;95(3):216–228. Available from: <http://dx.doi.org/10.1111/iep.12083>.
- [27] Matsuzaki J, Suzuki H, Tsugawa H, Watanabe M, Hossain S, Arai E, et al. Bile acids increase levels of microRNAs 221 and 222, leading to degradation of CDX2 during esophageal carcinogenesis. *Gastroenterology*. 2013 Dec;145(6):1300–1311. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/23933602> <http://dx.doi.org/10.1053/j.gastro.2013.08.008>.
- [28] Gonçalves RB, Coletta RD, Silvério KG, Benevides L, Casati MZ, da Silva JS, et al. Impact of smoking on inflammation: overview of molecular mechanisms. *Inflamm Res*. 2011 May;60(5):409–424. Available from: <http://dx.doi.org/10.1007/s00011-011-0308-7>.

- [29] Shiels MS, Katki HA, Freedman ND, Purdue MP, Wentzensen N, Trabert B, et al. Cigarette smoking and variations in systemic immune and inflammation markers. *J Natl Cancer Inst.* 2014 Nov;106(11). Available from: <http://dx.doi.org/10.1093/jnci/dju294>.
- [30] Vlachopoulos C, Aznaouridis K, Bratsas A, Ioakeimidis N, Dima I, Xaplanteris P, et al. Arterial stiffening and systemic endothelial activation induced by smoking: The role of COX-1 and COX-2. *Int J Cardiol.* 2015 Apr;189:293–298. Available from: <http://dx.doi.org/10.1016/j.ijcard.2015.04.029>.
- [31] Tsigos C, Kyrou I, Chala E, Tsapogas P, Stavridis JC, Raptis SA, et al. Circulating tumor necrosis factor alpha concentrations are higher in abdominal versus peripheral obesity. *Metabolism.* 1999 Oct;48(10):1332–1335.
- [32] Greenfield JR, Samaras K, Jenkins AB, Kelly PJ, Spector TD, Gallimore JR, et al. Obesity is an important determinant of baseline serum C-reactive protein concentration in monozygotic twins, independent of genetic influences. *Circulation.* 2004 Jun;109(24):3022–3028. Available from: <http://dx.doi.org/10.1161/01.CIR.0000130640.77501.79>.
- [33] Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. *Nat Rev Cancer.* 2004 Aug;4(8):579–591. Available from: <http://dx.doi.org/10.1038/nrc1408>.
- [34] Levine DM, Ek WE, Zhang R, Liu X, Onstad L, Sather C, et al. A genome-wide association study identifies new susceptibility loci for esophageal adenocarcinoma and Barrett's esophagus. *Nature genetics.* 2013 Dec;45(12):1487–93. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/24121790>.
- [35] Su Z, Gay LJ, Strange A, Palles C, Band G, Whiteman DC, et al. Common variants at the MHC locus and at chromosome 16q24.1 predispose to Barrett's esophagus. *Nature Genetics.* 2012 Oct;44(10):1131–1136. Available from: <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3459818&tool=pmcentrez&rendertype=abstract>.
- [36] Ek WE, Levine DM, D'Amato M, Pedersen NL, Magnusson PKE, Bresso F, et al. Germline genetic contributions to risk for esophageal adenocarcinoma, Barrett's esophagus, and gastroesophageal reflux. *Journal of the National Cancer Institute.* 2013 Nov;105(22):1711–1718.
- [37] Palles C, Chegwidzen L, Li X, Findlay JM, Farnham G, Giner FC, et al. Polymorphisms Near TBX5 and GDF7 Are Associated With Increased Risk for Barrett's Esophagus. *Gastroenterology.* 2015

Nov;148(2):367–378. Available from: <http://linkinghub.elsevier.com/retrieve/pii/S0016508514013341>  
<http://www.ncbi.nlm.nih.gov/pubmed/25447851>.

[38] Becker J, May A, Gerges C, Anders M, Veits L, Weise K, et al. Supportive evidence for FOXP1, BARX1, and FOXF1 as genetic risk loci for the development of esophageal adenocarcinoma. *Cancer Medicine*. 2015;.

[39] Jin L, Zuo XY, Su WY, Zhao XL, Yuan MQ, Han LZ, et al. Pathway-based analysis tools for complex diseases: a review. *Genomics Proteomics Bioinformatics*. 2014 Oct;12(5):210–220. Available from: <http://dx.doi.org/10.1016/j.gpb.2014.10.002>.

[40] Buas MF, Levine DM, Makar KW, Utsugi H, Onstad L, Li X, et al. Integrative post-genome-wide association analysis of CDKN2A and TP53 SNPs and risk of esophageal adenocarcinoma. *Carcinogenesis*. 2014 Dec;35(12):2740–2747. Available from: <http://www.carcin.oxfordjournals.org/cgi/-doi/10.1093/carcin/bgu207>.

[41] Amos CI, Wang LEE, Lee JE, Gershenwald JE, Chen WV, Fang S, et al. Genome-wide association study identifies novel loci predisposing to cutaneous melanoma. *Hum Mol Genet*. 2011 Dec;20(24):5012–5023. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/21926416> <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3298855&tool=pmcentrez&rendertype=abstract>.

[42] Laurie CC, Doheny KF, Mirel DB, Pugh EW, Bierut LJ, Bhangale T, et al. Quality control and quality assurance in genotypic data for genome-wide association studies. *Genetic Epidemiology*. 2010;34(6):591–602. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/20718045>.

[43] Schottenfeld D, Beebe-Dimmer J. Chronic inflammation: a common and important factor in the pathogenesis of neoplasia. *CA Cancer J Clin*. 2006;56(2):69–83.

[44] Santos CI, Costa-Pereira AP. Signal transducers and activators of transcription-from cytokine signalling to cancer biology. *Biochim Biophys Acta*. 2011 Aug;1816(1):38–49. Available from: <http://dx.doi.org/10.1016/j.bbcan.2011.03.003>.

[45] Konturek PC, Nikiforuk A, Kania J, Raithel M, Hahn EG, Mühldorfer S. Activation of NFkappaB represents the central event in the neoplastic progression associated with Barrett's esophagus: a possible link to the inflammation and overexpression of COX-2, PPARgamma and growth factors. *Dig Dis Sci*. 2004 Aug;49(7-8):1075–1083.

- [46] Beales ILP, Ogunwobi OO. Glycine-extended gastrin inhibits apoptosis in Barrett's oesophageal and oesophageal adenocarcinoma cells through JAK2/STAT3 activation. *J Mol Endocrinol*. 2009 Apr;42(4):305–318. Available from: <http://dx.doi.org/10.1677/JME-08-0096>.
- [47] Poehlmann A, Kuester D, Malfertheiner P, Guenther T, Roessner A. Inflammation and Barrett's carcinogenesis. *Pathol Res Pract*. 2012 May;208(5):269–280. Available from: <http://dx.doi.org/10.1016/j.prp.2012.03.007>.
- [48] Verbeke H, Hannelien V, Geboes K, Karel G, Van Damme J, Jo VD, et al. The role of CXC chemokines in the transition of chronic inflammation to esophageal and gastric cancer. *Biochim Biophys Acta*. 2012 Jan;1825(1):117–129. Available from: <http://dx.doi.org/10.1016/j.bbcan.2011.10.008>.
- [49] Singh S, Sharma AN, Murad MH, Buttar NS, El-Serag HB, Katzka DA, et al. Central adiposity is associated with increased risk of esophageal inflammation, metaplasia, and adenocarcinoma: a systematic review and meta-analysis. *Clin Gastroenterol Hepatol*. 2013 Nov;11(11):1399–1412.e7. Available from: <http://dx.doi.org/10.1016/j.cgh.2013.05.009>.
- [50] Abdalla SI, Sanderson IR, Fitzgerald RC. Effect of inflammation on cyclooxygenase (COX)-2 expression in benign and malignant oesophageal cells. *Carcinogenesis*. 2005 Sep;26(9):1627–1633. Available from: <http://dx.doi.org/10.1093/carcin/bgi114>.
- [51] O'Riordan JM, Abdel-latif MM, Ravi N, McNamara D, Byrne PJ, McDonald GSA, et al. Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. *Am J Gastroenterol*. 2005 Jun;100(6):1257–1264. Available from: <http://dx.doi.org/10.1111/j.1572-0241.2005.41338.x>.
- [52] Oh DS, DeMeester SR, Vallbohmer D, Mori R, Kuramochi H, Hagen JA, et al. Reduction of interleukin 8 gene expression in reflux esophagitis and Barrett's esophagus with antireflux surgery. *Arch Surg*. 2007 Jun;142(6):554–9; discussion 559–60. Available from: <http://dx.doi.org/10.1001/archsurg.142.6.554>.
- [53] Kundu JK, Surh YJ. Inflammation: gearing the journey to cancer. *Mutat Res*. 2008;659(1-2):15–30. Available from: <http://dx.doi.org/10.1016/j.mrrev.2008.03.002>.

- [54] Slattery ML, Wolff RK, Herrick J, Caan BJ, Samowitz W. Tumor markers and rectal cancer: support for an inflammation-related pathway. *Int J Cancer*. 2009 Oct;125(7):1698–1704. Available from: <http://dx.doi.org/10.1002/ijc.24467>.
- [55] Shiels MS, Engels EA, Shi J, Landi MT, Albanes D, Chatterjee N, et al. Genetic variation in innate immunity and inflammation pathways associated with lung cancer risk. *Cancer*. 2012 Nov;118(22):5630–5636. Available from: <http://dx.doi.org/10.1002/cncr.27605>.
- [56] Brenner DR, Brennan P, Boffetta P, Amos CI, Spitz MR, Chen C, et al. Hierarchical modeling identifies novel lung cancer susceptibility variants in inflammation pathways among 10,140 cases and 11,012 controls. *Hum Genet*. 2013 May;132(5):579–589. Available from: <http://dx.doi.org/10.1007/s00439-013-1270-y>.
- [57] Delaneau O, Marchini J, Zagury JF. A linear complexity phasing method for thousands of genomes. *Nat Methods*. 2012 Feb;9(2):179–181. Available from: <http://dx.doi.org/10.1038/nmeth.1785>.
- [58] Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. *Journal of the Royal Statistical Society Series B (Methodological)*. 1995;p. 289–300.
- [59] Pruim RJ, Welch RP, Sanna S, Teslovich TM, Chines PS, Gliedt TP, et al. LocusZoom: regional visualization of genome-wide association scan results. *Bioinformatics*. 2010 Sep;26(18):2336–2337. Available from: <http://dx.doi.org/10.1093/bioinformatics/btq419>.
- [60] Brinkley TE, Hsu FC, Beavers KM, Church TS, Goodpaster BH, Stafford RS, et al. Total and abdominal adiposity are associated with inflammation in older adults using a factor analysis approach. *J Gerontol A Biol Sci Med Sci*. 2012 Oct;67(10):1099–1106. Available from: <http://dx.doi.org/10.1093/gerona/gls077>.
- [61] Evangelou E, Ioannidis JPA. Meta-analysis methods for genome-wide association studies and beyond. *Nat Rev Genet*. 2013 Jun;14(6):379–389. Available from: <http://dx.doi.org/10.1038/nrg3472>.
- [62] Bernstein BE, Stamatoyannopoulos Ja, Costello JF, Ren B, Milosavljevic A, Meissner A, et al. The NIH Roadmap Epigenomics Mapping Consortium. *Nature biotechnology*. 2010;28(10):1045–1048. Available from: <http://dx.doi.org/10.1038/nbt1010-1045>.

- [63] "The\_GTEx\_Consortium". The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene regulation in humans. *Science*. 2015 May;348(6235):648–660. Available from: <http://dx.doi.org/10.1126/science.1262110>.
- [64] Kelner MJ, Bagnell RD, Montoya MA, Estes LA, Forsberg L, Morgenstern R. Structural organization of the microsomal glutathione S-transferase gene (MGST1) on chromosome 12p13.1-13.2. Identification of the correct promoter region and demonstration of transcriptional regulation in response to oxidative stress. *J Biol Chem*. 2000 Apr;275(17):13000–13006.
- [65] Johansson K, Järvliden J, Gogvadze V, Morgenstern R. Multiple roles of microsomal glutathione transferase 1 in cellular protection: a mechanistic study. *Free Radic Biol Med*. 2010 Dec;49(11):1638–1645. Available from: <http://dx.doi.org/10.1016/j.freeradbiomed.2010.08.013>.
- [66] Nebert DW, Vasiliou V. Analysis of the glutathione S-transferase (GST) gene family. *Hum Genomics*. 2004 Nov;1(6):460–464.
- [67] Jakobsson PJ, Thorén S, Morgenstern R, Samuelsson B. Identification of human prostaglandin E synthase: a microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target. *Proc Natl Acad Sci U S A*. 1999 Jun;96(13):7220–7225.
- [68] Zhang H, Liao LH, Liu SM, Lau KW, Lai AKC, Zhang JH, et al. Microsomal glutathione S-transferase gene polymorphisms and colorectal cancer risk in a Han Chinese population. *Int J Colorectal Dis*. 2007 Oct;22(10):1185–1194. Available from: <http://dx.doi.org/10.1007/s00384-007-0308-9>.
- [69] Ward LD, Kellis M. HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants. *Nucleic Acids Res*. 2012 Jan;40(Database issue):D930–D934. Available from: <http://dx.doi.org/10.1093/nar/gkr917>.
- [70] Gibbs JR, van der Brug MP, Hernandez DG, Traynor BJ, Nalls MA, Lai SL, et al. Abundant quantitative trait loci exist for DNA methylation and gene expression in human brain. *PLoS Genet*. 2010 May;6(5):e1000952. Available from: <http://dx.doi.org/10.1371/journal.pgen.1000952>.
- [71] Xian W, Ho KY, Crum CP, McKeon F. Cellular origin of Barrett's esophagus: Controversy and therapeutic implications. *Gastroenterology*. 2012 Jun;142(7):1424–1430. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/22537611>.


- [72] McDonald SAC, Lavery D, Wright NA, Jansen M. Barrett oesophagus: lessons on its origins from the lesion itself. *Nat Rev Gastroenterol Hepatol*. 2015 Jan;12(1):50–60. Available from: <http://dx.doi.org/10.1038/nrgastro.2014.181>.
- [73] Moons LMG, Kuipers EJ, Rygiel AM, Groothuismink AZM, Geldof H, Bode WA, et al. COX-2 CA-haplotype is a risk factor for the development of esophageal adenocarcinoma. *American Journal of Gastroenterology*. 2007;102(11):2373–2379. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/17581270?dopt=Citation>.
- [74] Kristinsson JO, van Westerveld P, te Morsche RHM, Roelofs HMJ, Wobbes T, Witteman BJM, et al. Cyclooxygenase-2 polymorphisms and the risk of esophageal adeno- or squamous cell carcinoma. *World journal of gastroenterology : WJG*. 2009;15(28):3493–3497. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/19630103>.
- [75] Nan H, Hutter CM, Lin Y, Jacobs EJ, Ulrich CM, White E, et al. Association of Aspirin and NSAID Use With Risk of Colorectal Cancer According to Genetic Variants. *JAMA*. 2015;313(11):1133. Available from: <http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.2015.1815>.
- Tselepis C, Perry I, Dawson C, Hardy R, Darnton J, McConkey C, Stuart R, Wright NA, Harrison RF, Jankowski J. Tumour necrosis factor alpha in Barrett's metaplasia: a novel mechanism of action. **Oncogene** 2002;39:6071-81.

**Table 1. Study participant characteristics<sup>†</sup>.**

	<b>Controls<sup>#</sup></b>		<b>BE</b>		<b>EA</b>	
	(n=3207)		(n=3295)		(n=2515)	
	N	%	N	%	N	%
Age (years)						
<50	726	22.6	449	13.7	189	7.6
50-59	885	27.6	780	23.7	547	21.9
60-69	963	30.0	1011	30.7	884	35.4
70+	633	19.7	1048	31.9	875	35.1
Sex						
Female	880	27.4	806	24.5	320	12.7
Male	2327	72.6	2489	75.5	2195	87.3
BMI						
<25	786	36.3	425	20.7	245	24.6
25-29.99	944	43.6	882	42.9	455	45.7
30-34.99	307	14.2	521	25.3	201	20.2
35+	130	6.0	230	11.2	95	9.5
Smoking status						
No	889	40.9	798	33.7	348	24.7
Yes	1284	59.1	1570	66.3	1062	75.3
Smoking (p-y) <sup>a</sup>						
None	889	41.3	798	44.5	348	32.8
<15	358	16.6	320	17.9	156	14.7
15-29	326	15.1	232	12.9	160	15.1
30-44	273	12.7	198	11.0	173	16.3
45+	309	14.3	244	13.6	225	21.2
NSAID use						
Never	814	44.0	503	42.8	381	46.2
Ever	1038	56.0	672	57.2	444	53.8
Heartburn/reflux <sup>b</sup>						
No	1448	80.6	957	49.0	563	56.2
Yes	349	19.4	996	51.0	438	43.8
Inflammation score						
Low	818	46.2	235	14.3	142	20.9
Medium	381	21.5	262	16.0	137	20.2
High	571	32.3	1143	69.7	400	58.9

<sup>†</sup>Numbers do not add to total subjects due to missing data; <sup>#</sup>3 participants were excluded from the control group for comparison to BE case patients due to relatedness; <sup>a</sup>Pack-years, <sup>b</sup>Weekly symptoms

Figure 1. Overview of principal components-based method for pathway-level and gene-level association analyses.



**Table 2. Assessment of pathway-level associations with risk of Barrett's esophagus (BE) or esophageal adenocarcinoma (EA).**

Pathway	Genes	Variants <sup>a</sup>	BE			EA		
			PCs <sup>b</sup>	P <sup>c</sup>	q <sup>d</sup>	PCs <sup>b</sup>	P <sup>c</sup>	q <sup>d</sup>
COX	40	1241	40	0.006	0.03	40	0.20	0.60
Cytokines	184	2622	110	0.10	0.21	109	0.28	0.60
Oxidative stress	115	1958	73	0.13	0.21	73	0.58	0.60
Immune/HLA	32	1036	10	0.59	0.74	10	0.60	0.60
NFκB	125	1681	110	0.84	0.84	109	0.42	0.60

<sup>a</sup>Total number of single nucleotide polymorphisms (SNPs) selected for analysis; <sup>b</sup>Pathway-level principal components (PCs) included in the logistic regression model; <sup>c</sup>Likelihood ratio P value; <sup>d</sup>False discovery rate (FDR) q value.

**Table 3. Assessment of first 10 gene-level associations with risk of BE.**

	<b>Gene</b>		<b>Variants<sup>a</sup></b>	<b>PCs<sup>b</sup></b>	<b>P<sup>c</sup></b>	<b>q<sup>d</sup></b>
<b>1</b>	MGST1	Microsomal glutathione S-transferase 1	36	3	0.0005	0.005
<b>2</b>	PTGER3	Prostaglandin E receptor 3 (subtype EP3)	185	4	0.11	0.51
<b>3</b>	PPARG	Peroxisome proliferator-activated receptor gamma	121	3	0.15	0.51
<b>4</b>	TBXAS1	Thromboxane A synthase 1 (platelet)	176	5	0.29	0.58
<b>5</b>	IL12RB2	Interleukin 12 receptor, beta 2	29	3	0.29	0.58
<b>6</b>	CYP19A1	Cytochrome P450, family 19, subfamily A, polypeptide 1	50	3	0.40	0.66
<b>7</b>	MMP2	Matrix metalloproteinase 2	25	3	0.48	0.69
<b>8</b>	PPARA	Peroxisome proliferator-activated receptor alpha	54	3	0.72	0.80
<b>9</b>	MGST2	Microsomal glutathione S-transferase 2	57	4	0.72	0.80
<b>10</b>	PTGES	Prostaglandin E synthase	11	3	1.00	1.00


<sup>a</sup>Total number of SNPs selected for analysis of the indicated gene; <sup>b</sup>Gene-level principal components (PCs) included in the logistic regression model; <sup>c</sup>Likelihood ratio P value; <sup>d</sup>False discovery rate (FDR) q value.

**Table 4. Assessment of *MGST1* SNPs (n=36) and risk of BE<sup>#</sup>**

	SNP	Chr	Position	Alleles <sup>a</sup>	Controls		BE cases		OR <sup>c</sup>	95% CI	P	q <sup>d</sup>
					N	MAF <sup>b</sup>	N	MAF <sup>b</sup>				
1	rs4149203	12	16514921	T/C	3203	0.308	3288	0.346	1.16	(1.08-1.26)	0.0001	0.001
2	rs3852575	12	16516260	T/C	3203	0.304	3288	0.34	1.16	(1.08-1.25)	0.0001	0.001
3	rs7312090	12	16515945	T/C	3203	0.304	3288	0.34	1.16	(1.07-1.25)	0.0002	0.001
4	rs4149204	12	16515062	C/T	3203	0.307	3288	0.342	1.16	(1.07-1.25)	0.0002	0.001
5	rs4149207	12	16517491	T/C	3203	0.306	3288	0.338	1.14	(1.06-1.23)	0.0008	0.005
6	rs4149208	12	16517581	T/C	3203	0.306	3288	0.338	1.14	(1.06-1.23)	0.0008	0.005
7	rs3759207	12	16516710	C/T	3203	0.31	3288	0.34	1.14	(1.05-1.23)	0.0012	0.006
8	rs4149195	12	16512128	G/A	3203	0.109	3288	0.125	1.20	(1.07-1.35)	0.0013	0.006
9	rs2239676	12	16500448	G/C	3203	0.096	3288	0.113	1.19	(1.06-1.34)	0.0033	0.013
10	rs4149187	12	16500071	G/C	3203	0.098	3288	0.114	1.18	(1.05-1.32)	0.0061	0.022
11	rs2239677	12	16500680	A/G	3203	0.021	3288	0.027	1.38	(1.09-1.75)	0.0077	0.025
12	rs2239675	12	16500265	G/A	3203	0.172	3288	0.187	1.12	(1.02-1.23)	0.0172	0.049
13	rs4149186	12	16498700	C/A	3203	0.215	3288	0.235	1.11	(1.02-1.21)	0.0179	0.049
14	rs2975138	12	16501551	A/G	3203	0.237	3288	0.256	1.10	(1.02-1.20)	0.0192	0.049

<sup>#</sup>Results for n=14 SNPs satisfying FDR  $q < 0.05$ , <sup>a</sup>Minor/major alleles, <sup>b</sup>Minor allele frequency, <sup>c</sup>Odds ratio, adjusted for age, sex,  $PC_{1,AIM}$ - $PC_{4,AIM}$  using additive model (per-allele), <sup>d</sup>False discovery rate (FDR)

**Figure 2. Regional association plot for n=36 genotyped SNPs at the *MGST1* gene locus.** The top-ranked SNP associated with risk of BE is shown in solid purple. SNPs are ordered by genomic location. The color scheme indicates LD between the top-ranked SNP and other SNPs in the region using  $r^2$  values calculated from the 1000 Genomes Project. The y axis shows  $-\log_{10}(P)$  values computed from 3295 BE cases and 3204 controls. The recombination rate from CEU (Utah residents of Northern and Western European ancestry) HapMap data (right y axis) is shown in light blue.



**Table 5. Assessment of *MGST1* SNPs and risk of BE in an independent study sample of 1,851 BE cases and 3,496 control participants (Oxford)<sup>#</sup>.**

	SNP	Allele <sup>a</sup>	BEACON		Oxford		Meta-analysis	
			OR	P	OR	P	OR	P
1	rs4149203	T	1.16	0.0001	1.08	0.0718	1.13	3.46E-05
2	rs3852575	T	1.16	0.0001	1.08	0.0661	1.13	4.04E-05
3	rs7312090	T	1.16	0.0002	1.08	0.0678	1.13	5.12E-05
4	rs4149204	C	1.16	0.0002	1.08	0.0668	1.13	5.25E-05
5	rs4149207	T	1.14	0.0008	1.05	0.2676	1.10	0.0011
6	rs4149208	T	1.14	0.0008	1.05	0.2837	1.10	0.0013
7	rs3759207	C	1.14	0.0012	1.05	0.2649	1.10	0.0015
8	rs4149195	G	1.20	0.0013	1.09	0.2160	1.15	0.0012
9	rs2239676	G	1.19	0.0033	0.99	0.9402	1.10	0.0293
10	rs4149187	G	1.18	0.0061	0.99	0.8894	1.09	0.0461
11	rs2239675	G	1.12	0.0172	1.00	0.9882	1.07	0.0704
12	rs4149186	C	1.11	0.0179	0.99	0.7973	1.05	0.1081
13	rs2975138	A	1.10	0.0192	1.01	0.8523	1.06	0.0605

<sup>#</sup>Results for n=13 SNPs available for analysis among the 14 variants listed in Table 4; <sup>a</sup>Effect allele (all ORs represent per-allele risk estimates under an additive model)

## **SUPPLEMENTAL DATA**

**Table S1. Cox pathway genes selected for analysis.**

*[See Excel spreadsheet for list of selected genes in other four pathways]*

	<b>Gene</b>	<b>Chr</b>	<b>Start</b>	<b>End</b>	<b>bp</b>
1	AKR1C1	10	5000044	5022159	22115
2	AKR1C2	10	5029967	5060207	30240
3	AKR1C3	10	5077549	5149878	72329
4	CXCL8	4	74606223	74609433	3210
5	CYP19A1	15	51500254	51630807	130553
6	FIGF	23	15363713	15402498	38785
7	IL12A	3	159706537	159713806	7269
8	IL12B	5	158741791	158757481	15690
9	IL12RB1	19	18170411	18197697	27286
10	IL12RB2	1	67773047	67862583	89536
11	MGST1	12	16500076	16517343	17267
12	MGST2	4	140586922	140661899	74977
13	MGST3	1	165600098	165631033	30935
14	MMP1	11	102660651	102668891	8240
15	MMP2	16	55512883	55540603	27720
16	MMP3	11	102706532	102714320	7788
17	MMP9	20	44637547	44645200	7653
18	PPARA	22	46546424	46639653	93229
19	PPARD	6	35310335	35395955	85620
20	PPARG	3	12328867	12475855	146988
21	PTGDR	14	52734431	52743442	9011
22	PTGDR2	11	60618413	60623444	5031
23	PTGDS	9	139871956	139879887	7931
24	PTGER1	19	14583278	14586174	2896
25	PTGER2	14	52781113	52795324	14211
26	PTGER3	1	71318036	71513491	195455
27	PTGER4	5	40679600	40693837	14237
28	PTGES	9	132500610	132515326	14716
29	PTGES2	9	130882972	130890741	7769
30	PTGFR	1	78769568	79005434	235866
31	PTGIR	19	47123726	47128354	4628
32	PTGIS	20	48123992	48184683	60691
33	PTGS1	9	125133359	125157982	24623
34	PTGS2	1	186640923	186649559	8636
35	TBXA2R	19	3594504	3606658	12154
36	TBXAS1	7	139476850	139720125	243275
37	TIMP3	22	33197687	33259030	61343
38	VEGFA	6	43737921	43754224	16303
39	VEGFB	11	64002266	64006258	3992
40	VEGFC	4	177604689	177713881	109192

**Table S2. Gene-level associations with risk of EA.**

	<b>Gene</b>		<b>Variants<sup>a</sup></b>	<b>PCs<sup>b</sup></b>	<b>P<sup>c</sup></b>	<b>q<sup>d</sup></b>
<b>1</b>	MGST1	Microsomal glutathione S-transferase 1	36	3	0.07	0.39
<b>2</b>	TBXAS1	Thromboxane A synthase 1 (platelet)	176	5	0.17	0.39
<b>3</b>	IL12RB2	Interleukin 12 receptor, beta 2	29	3	0.21	0.39
<b>4</b>	PTGER1	Prostaglandin E receptor 1 (subtype EP1), 42kDa	10	3	0.22	0.39
<b>5</b>	PTGER3	Prostaglandin E receptor 3 (subtype EP3)	185	4	0.22	0.39
<b>6</b>	MMP2	Matrix metalloproteinase 2	25	3	0.25	0.39
<b>7</b>	PPARG	Peroxisome proliferator-activated receptor gamma	121	3	0.27	0.39
<b>8</b>	PPARD	Peroxisome proliferator-activated receptor delta	67	3	0.48	0.60
<b>9</b>	IL12B	Interleukin 12B	31	3	0.77	0.85
<b>10</b>	CYP19A1	Cytochrome P450, family 19, subfamily A, polypeptide 1	50	3	0.91	0.91

<sup>a</sup>Total number of SNPs selected for analysis of the indicated gene; <sup>b</sup>Gene-level principal components (PCs) included in the logistic regression model; <sup>c</sup>Likelihood ratio P value; <sup>d</sup>False discovery rate (FDR) q value.

**Table S3. Assessment of *MGST1* SNPs (n=14, Table 4) and risk of EA**

	SNP	Chr	Position	Alleles <sup>a</sup>	Controls		EA cases		OR <sup>c</sup>	95% CI	P	q <sup>d</sup>
					N	MAF <sup>b</sup>	N	MAF <sup>b</sup>				
1	rs4149195	12	16512128	G/A	3206	0.109	2495	0.12	1.17	(1.03-1.32)	0.016	0.04
2	rs2239676	12	16500448	G/C	3206	0.096	2495	0.111	1.17	(1.03-1.33)	0.018	0.04
3	rs3852575	12	16516260	T/C	3206	0.304	2495	0.331	1.11	(1.02-1.21)	0.019	0.04
4	rs4149204	12	16515062	C/T	3206	0.307	2495	0.334	1.11	(1.02-1.20)	0.020	0.04
5	rs3759207	12	16516710	C/T	3206	0.31	2495	0.335	1.10	(1.01-1.20)	0.023	0.04
6	rs4149207	12	16517491	T/C	3206	0.307	2495	0.332	1.10	(1.01-1.20)	0.023	0.04
7	rs7312090	12	16515945	T/C	3206	0.304	2495	0.331	1.10	(1.01-1.20)	0.024	0.04
8	rs4149208	12	16517581	T/C	3206	0.307	2495	0.332	1.10	(1.01-1.20)	0.025	0.04
9	rs4149203	12	16514921	T/C	3206	0.308	2495	0.334	1.10	(1.01-1.19)	0.034	0.05
10	rs2975138	12	16501551	A/G	3206	0.237	2495	0.253	1.10	(1.00-1.21)	0.041	0.06
11	rs4149187	12	16500071	G/C	3206	0.098	2495	0.111	1.14	(1.00-1.29)	0.047	0.06
12	rs2239675	12	16500265	G/A	3206	0.172	2495	0.185	1.09	(0.98-1.21)	0.114	0.13
13	rs4149186	12	16498700	C/A	3206	0.215	2495	0.228	1.07	(0.97-1.18)	0.174	0.19
14	rs2239677	12	16500680	A/G	3206	0.021	2495	0.024	1.18	(0.90-1.54)	0.232	0.23

<sup>a</sup>Minor/major alleles, <sup>b</sup>Minor allele frequency, <sup>c</sup>Odds ratio, adjusted for age, sex, PC<sub>AIM,1</sub>-PC<sub>AIM,4</sub> using additive model (per-allele), <sup>d</sup>False discovery rate (FDR)


**Table S4. Genotype-Tissue Expression (GTEx) analysis of *MGST1* SNPs (n=14, Table 4).**

Results from Table 4					GTEx				
	SNP	Alleles <sup>a</sup>	OR <sup>b</sup>	P	Gene	Tissue	Allele <sup>c</sup>	Effect size <sup>d</sup>	P <sup>e</sup>
1	rs4149203	T/C	1.16	0.0001	MGST1	Esophagus Mucosa	A	-0.27	0.074
2	rs3852575	T/C	1.16	0.0001	MGST1	Esophagus Mucosa	A	-0.24	0.11
3	rs7312090	T/C	1.16	0.0002	MGST1	Esophagus Mucosa	A	-0.22	0.13
4	rs4149204	C/T	1.16	0.0002	MGST1	Esophagus Mucosa	C	-0.22	0.15
5	rs4149207	T/C	1.14	0.0008	MGST1	Esophagus Mucosa	T	-0.26	0.11
6	rs4149208	T/C	1.14	0.0008	MGST1	Esophagus Mucosa	T	-0.26	0.11
7	rs3759207	C/T	1.14	0.0012	MGST1	Esophagus Mucosa	C	-0.22	0.14
8	rs4149195	G/A	1.20	0.0013	MGST1	Esophagus Mucosa	A	0.27	0.20
9	rs2239676	G/C	1.19	0.0033	MGST1	Esophagus Mucosa	C	0.15	0.52
10	rs4149187	G/C	1.18	0.0061	MGST1	Esophagus Mucosa	C	-0.28	0.19
11	rs2239677	A/G	1.38	0.0077	MGST1	N/A	N/A	N/A	N/A
12	rs2239675	G/A	1.12	0.0172	MGST1	Esophagus Mucosa	A	0.13	0.50
13	rs4149186	C/A	1.11	0.0179	MGST1	Esophagus Mucosa	G	-0.57	0.000079
14	rs2975138	A/G	1.10	0.0192	MGST1	Esophagus Mucosa	G	0.74	1.20E-07


<sup>a</sup>Minor/major alleles, <sup>b</sup>Odds ratio for BE, adjusted for age, sex, PC<sub>AIM,1</sub>-PC<sub>AIM,4</sub> using additive model, <sup>c</sup>Effect allele, <sup>d</sup>P value for assessing a linear trend in RNA expression level relative to genotype, <sup>e</sup>Derived from linear regression analysis

**Figure S1. Genotype-Tissue Expression (GTEx) box plots of *MGST1* RNA expression levels in esophageal mucosa versus rs4149186 (A) or rs2975138 (B) germline genotype.** Plots were directly extracted from the GTEx Project website and labeled with the indicated genotypes. P values were derived from linear regression analyses stored in the GTEx database. Individual data points are displayed as gray circles. Median expression levels are plotted as horizontal black bars within the gray boxes. The “G” and “T” alleles of rs4149186 (A) correspond to the “C” and “A” alleles in Table 4.

**A**



**B**



**Table S5. Selected *MGST1* SNPs and BE risk, stratified by smoking history (ever/never) (A), pack-year smoking history (B), BMI (C), reflux history (D), NSAID use (E), or inflammation score (F).** Stratum-specific odds ratios (ORs) were adjusted for age, sex, and PC<sub>AIM,1</sub>-PC<sub>AIM,4</sub> using an additive model (per-allele); interaction P values (P-int) were derived from likelihood ratio tests.

**A.**

SNP	Never smokers	Ever smokers	P-int
	OR (95% CI)	OR (95% CI)	
	P	P	
rs4149203	1.16 (1.00-1.34) 0.050	1.17 (1.04-1.31) 0.007	0.89
rs3852575	1.18 (1.02-1.37) 0.023	1.16 (1.04-1.30) 0.010	0.84
rs7312090	1.18 (1.02-1.36) 0.029	1.16 (1.04-1.30) 0.010	0.89
rs4149204	1.19 (1.03-1.37) 0.021	1.16 (1.04-1.30) 0.010	0.82
rs4149207	1.14 (0.98-1.32) 0.090	1.14 (1.02-1.28) 0.021	0.92
rs4149208	1.14 (0.98-1.32) 0.090	1.14 (1.02-1.28) 0.021	0.92
rs3759207	1.15 (0.99-1.33) 0.059	1.13 (1.01-1.27) 0.034	0.88
rs4149195	1.22 (0.98-1.52) 0.076	1.24 (1.05-1.47) 0.013	0.94

**B.**

SNP	Pack-years of cigarette smoking					P-int
	0	>0 & <15	15-29	30-44	45+	
	OR (95% CI) P	OR (95% CI) P	OR (95% CI) P	OR (95% CI) P	OR (95% CI) P	
rs4149203	1.16 (1.00-1.34) 0.050	1.17 (0.93-1.48) 0.172	1.00 (0.78-1.29) 0.990	1.18 (0.88-1.59) 0.276	1.17 (0.90-1.53) 0.237	0.91
rs3852575	1.18 (1.02-1.37) 0.023	1.15 (0.91-1.45) 0.237	0.98 (0.76-1.27) 0.871	1.19 (0.88-1.61) 0.252	1.14 (0.87-1.49) 0.335	0.94
rs7312090	1.18 (1.02-1.36) 0.029	1.15 (0.91-1.45) 0.237	0.98 (0.76-1.27) 0.876	1.19 (0.88-1.61) 0.252	1.13 (0.87-1.48) 0.363	0.93
rs4149204	1.19 (1.03-1.37) 0.021	1.16 (0.92-1.46) 0.219	0.99 (0.76-1.28) 0.926	1.17 (0.87-1.58) 0.308	1.11 (0.85-1.45) 0.442	0.74
rs4149207	1.14 (0.98-1.32) 0.090	1.13 (0.89-1.43) 0.306	0.93 (0.72-1.20) 0.570	1.31 (0.97-1.78) 0.082	1.09 (0.83-1.42) 0.547	0.83
rs4149208	1.14 (0.98-1.32) 0.090	1.13 (0.89-1.43) 0.306	0.93 (0.72-1.20) 0.570	1.31 (0.97-1.78) 0.082	1.09 (0.83-1.42) 0.547	0.83
rs3759207	1.15 (0.99-1.33) 0.059	1.14 (0.90-1.44) 0.280	0.93 (0.72-1.20) 0.574	1.27 (0.94-1.71) 0.125	1.05 (0.80-1.37) 0.716	0.86
rs4149195	1.22 (0.98-1.52) 0.076	1.14 (0.80-1.61) 0.468	1.08 (0.73-1.60) 0.702	1.33 (0.87-2.04) 0.191	1.52 (1.02-2.27) 0.041	0.46

Table S5 (continued).

C.

SNP	BMI				P-int
	<25	25-29.9	30-34.9	35+	
	OR (95% CI) P	OR (95% CI) P	OR (95% CI) P	OR (95% CI) P	
rs4149203	1.22 (1.03-1.46) 0.025	1.19 (1.03-1.37) 0.015	0.99 (0.79-1.24) 0.918	1.03 (0.74-1.44) 0.870	0.27
rs3852575	1.24 (1.04-1.48) 0.016	1.19 (1.03-1.37) 0.016	1.00 (0.79-1.25) 0.970	1.01 (0.72-1.42) 0.953	0.25
rs7312090	1.24 (1.04-1.47) 0.019	1.19 (1.03-1.37) 0.015	0.98 (0.78-1.24) 0.885	1.01 (0.72-1.42) 0.935	0.25
rs4149204	1.25 (1.04-1.49) 0.014	1.18 (1.02-1.36) 0.021	0.99 (0.79-1.25) 0.957	1.03 (0.73-1.45) 0.863	0.27
rs4149207	1.19 (0.99-1.42) 0.058	1.15 (1.00-1.33) 0.049	1.04 (0.83-1.30) 0.751	1.01 (0.72-1.42) 0.971	0.53
rs4149208	1.19 (0.99-1.42) 0.058	1.15 (1.00-1.33) 0.049	1.04 (0.83-1.30) 0.751	1.01 (0.72-1.42) 0.971	0.53
rs3759207	1.18 (0.99-1.41) 0.072	1.15 (1.00-1.33) 0.050	1.04 (0.83-1.31) 0.731	1.02 (0.73-1.44) 0.898	0.65
rs4149195	1.15 (0.88-1.51) 0.294	1.35 (1.09-1.66) 0.006	1.14 (0.81-1.61) 0.437	1.01 (0.62-1.65) 0.955	0.47

D.

SNP	Weekly heartburn/reflux		P-int
	No	Yes	
	OR (95% CI) P	OR (95% CI) P	
rs4149203	1.23 (1.09-1.40) 0.001	1.13 (0.94-1.36) 0.186	0.53
rs3852575	1.23 (1.08-1.39) 0.001	1.14 (0.94-1.37) 0.177	0.57
rs7312090	1.23 (1.08-1.39) 0.002	1.14 (0.94-1.37) 0.175	0.58
rs4149204	1.23 (1.08-1.40) 0.001	1.14 (0.95-1.37) 0.156	0.61
rs4149207	1.18 (1.04-1.34) 0.011	1.15 (0.95-1.38) 0.145	0.96
rs4149208	1.18 (1.04-1.34) 0.011	1.15 (0.95-1.38) 0.145	0.96
rs3759207	1.18 (1.04-1.34) 0.011	1.14 (0.95-1.37) 0.159	0.95
rs4149195	1.33 (1.10-1.60) 0.003	1.30 (0.97-1.73) 0.077	0.94

**Table S5 (continued).**

**E.**

SNP	NSAID use		P-int
	Never	Ever	
	OR (95% CI) P	OR (95% CI) P	
rs4149203	1.28 (1.08-1.52) 0.005	1.08 (0.93-1.25) 0.306	0.14
rs3852575	1.29 (1.09-1.54) 0.004	1.07 (0.92-1.24) 0.370	0.11
rs7312090	1.28 (1.08-1.52) 0.005	1.07 (0.92-1.25) 0.355	0.13
rs4149204	1.29 (1.09-1.53) 0.004	1.07 (0.92-1.24) 0.404	0.11
rs4149207	1.25 (1.05-1.48) 0.013	1.11 (0.95-1.29) 0.184	0.31
rs4149208	1.25 (1.05-1.48) 0.013	1.11 (0.95-1.29) 0.184	0.31
rs3759207	1.25 (1.05-1.49) 0.011	1.09 (0.94-1.27) 0.257	0.24
rs4149195	1.15 (0.90-1.49) 0.267	1.42 (1.14-1.78) 0.002	0.25

**F.**

SNP	Inflammation index			P-int
	Low	Medium	High	
	OR (95% CI) P	OR (95% CI) P	OR (95% CI) P	
rs4149203	1.22 (0.98-1.52) 0.0707	1.14 (0.90-1.45) 0.2764	1.15 (0.98-1.33) 0.0817	0.74
rs3852575	1.24 (1.00-1.54) 0.0547	1.11 (0.87-1.42) 0.3817	1.14 (0.98-1.33) 0.0961	0.79
rs7312090	1.24 (1.00-1.54) 0.0547	1.12 (0.88-1.43) 0.3456	1.13 (0.97-1.32) 0.1101	0.77
rs4149204	1.24 (1.00-1.54) 0.0555	1.12 (0.88-1.43) 0.3413	1.14 (0.98-1.33) 0.0903	0.81
rs4149207	1.26 (1.01-1.57) 0.04	1.11 (0.87-1.41) 0.4097	1.13 (0.97-1.32) 0.1092	0.92
rs4149208	1.26 (1.01-1.57) 0.04	1.11 (0.87-1.41) 0.4097	1.13 (0.97-1.32) 0.1092	0.92
rs3759207	1.27 (1.02-1.58) 0.0305	1.09 (0.86-1.39) 0.4772	1.14 (0.97-1.33) 0.1023	0.92
rs4149195	1.34 (0.97-1.84) 0.0757	1.20 (0.84-1.73) 0.3127	1.30 (1.03-1.64) 0.029	0.94

**Table S6. Functional annotations for top *MGST1* SNPs associated with risk of BE.**


SNP	dbSNP <sup>a</sup>	Motifs <sup>b</sup>	eQTL <sup>c</sup>	Enhancer histone marks <sup>d</sup>	DNase <sup>e</sup>	Proteins bound <sup>f</sup>
rs4149203	INT	Pou5f1, Sox	Cerebellum	Adipose Nuclei; Mesenchymal SC-Derived Adipocyte Cultured Cells; Duodenum Mucosa	.	.
rs3852575	INT	BRCA1, Foxp1, Hic1, NF-I, RREB-1, TATA	Cerebellum	.	.	.
rs7312090	INT	.	Cerebellum	.	.	.
rs4149204	INT	NRSF, Sin3Ak-20	Cerebellum	Adipose Nuclei; Mesenchymal SC-Derived Adipocyte Cultured Cells	.	.
rs3759207 (rs4149203: $r^2=0.82$ )	INT	Dbx1, GATA, HNF1	Cerebellum	.	.	.
rs2287152 (rs4149203: $r^2=0.97$ )	INT	En-1	Cerebellum	Adipose Nuclei; Mesenchymal SC-Derived Adipocyte Cultured Cells; Gastric	undifferentiated ESC; choroid plexus epithelial cells	POL2

<sup>a</sup>dbSNP functional annotation (INT: intronic), <sup>b</sup>Predicted binding motifs altered, <sup>c</sup>Expression quantitative trait locus (eQTL), <sup>d</sup>Regulatory chromatin states (NIH Roadmap), <sup>e</sup>DNase hypersensitivity (ENCODE), <sup>f</sup>Protein recruitment determined by chromatin-immunoprecipitation (ENCODE). Annotations extracted from HaploReg v2 (<http://www.broadinstitute.org/mammals/haploreg>).

**Table S7. Distribution of missing values for indicated covariates in the primary BEACON GWAS dataset.**

	<b>Controls</b>		<b>BE</b>		<b>EA</b>	
	(n=2185)		(n=2413)		(n=1512)	
	N	%	N	%	N	%
Age	0	0.0	0	0.0	0	0.0
Sex	0	0.0	0	0.0	0	0.0
BMI	18	0.8	355	14.7	516	34.1
Smoking status	12	0.5	45	1.9	102	6.7
Smoking (pack-years)	30	1.4	621	25.7	450	29.8
NSAID use	333	15.2	1238	51.3	687	45.4
Weekly heartburn or reflux	388	17.8	460	19.1	511	33.8
Inflammation score	415	19.0	773	32.0	833	55.1

**Figure S2. Regional association plot for n=36 genotyped SNPs at the *MGST1* gene locus.** The top-ranked variant among a cluster of six 5' SNPs associated with risk of BE (FDR  $q < 0.05$ ) is shown in solid purple. SNPs are ordered by genomic location. The color scheme indicates LD between the top-ranked SNP and other SNPs in the region using  $r^2$  values calculated from the 1000 Genomes Project. The y axis shows  $-\log_{10}(P)$  values computed from 3295 BE cases and 3204 controls. The recombination rate from CEU (Utah residents of Northern and Western European ancestry) HapMap data (right y axis) is shown in light blue.



**Figure S3. NIH Roadmap Epigenome Atlas characterization of the *MGST1* genomic locus.** Multiple transcript variants for *MGST1* are indicated (nc, non-coding). Patterns of DNA methylation (Bisulfite-Seq) and key histone modifications (H3K27me3, H3K4me3, H3K9me3) in esophageal tissue are displayed. The locus is segmented into regions of “integrative chromatin states” based on a Hidden Markov Model (HMM)-based algorithm trained on 127 epigenomes (<http://www.roadmapepigenomics.org/>). Red: Active TSS, Orange Red: Flanking Active TSS, LimeGreen: Transcr. at gene 5' and 3', Green: Strong transcription, DarkGreen: Weak transcription, GreenYellow: Genic enhancers, Yellow: Enhancers, Medium Aquamarine: ZNF genes & repeats, PaleTurquoise: Heterochromatin, IndianRed: Bivalent/Poised TSS, DarkSalmon: Flanking Bivalent TSS/Enh, DarkKhaki: Bivalent Enhancer, Silver: Repressed PolyComb, Gainsboro: Weak Repressed PolyComb, White: Quiescent/Low.

